These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 20941947)

  • 1. Cutaneous reactions to epidermal growth factor receptor inhibitors.
    Pomerantz RG; Mirvish ED; Geskin LJ
    J Drugs Dermatol; 2010 Oct; 9(10):1229-34. PubMed ID: 20941947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors.
    Tan EH; Chan A
    Ann Pharmacother; 2009 Oct; 43(10):1658-66. PubMed ID: 19755624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of the cutaneous side effects of therapeutic epidermal growth factor receptor inhibition.
    Reck M; Gutzmer R
    Onkologie; 2010; 33(8-9):470-9. PubMed ID: 20838065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results.
    Boone SL; Rademaker A; Liu D; Pfeiffer C; Mauro DJ; Lacouture ME
    Oncology; 2007; 72(3-4):152-9. PubMed ID: 18160805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors.
    Osio A; Mateus C; Soria JC; Massard C; Malka D; Boige V; Besse B; Robert C
    Br J Dermatol; 2009 Sep; 161(3):515-21. PubMed ID: 19466958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician.
    Gutzmer R; Becker JC; Enk A; Garbe C; Hauschild A; Leverkus M; Reimer G; Treudler R; Tsianakas A; Ulrich C; Wollenberg A; Homey B
    J Dtsch Dermatol Ges; 2011 Mar; 9(3):195-203. PubMed ID: 21059173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.
    Lynch TJ; Kim ES; Eaby B; Garey J; West DP; Lacouture ME
    Oncologist; 2007 May; 12(5):610-21. PubMed ID: 17522250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nail toxicity associated with epidermal growth factor receptor inhibitor therapy.
    Fox LP
    J Am Acad Dermatol; 2007 Mar; 56(3):460-5. PubMed ID: 17147969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The management of EGFR inhibitor adverse events: a case series and treatment paradigm.
    Wnorowski AM; de Souza A; Chachoua A; Cohen DE
    Int J Dermatol; 2012 Feb; 51(2):223-32. PubMed ID: 22250636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acneiform eruptions induced by epidermal growth factor receptor inhibitors: treatment with oral isotretinoin.
    Requena C; Llombart B; Sanmartín O
    Cutis; 2012 Aug; 90(2):77-80. PubMed ID: 22988651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life.
    Joshi SS; Ortiz S; Witherspoon JN; Rademaker A; West DP; Anderson R; Rosenbaum SE; Lacouture ME
    Cancer; 2010 Aug; 116(16):3916-23. PubMed ID: 20564072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor.
    Shin JU; Park JH; Cho BC; Lee JH
    Dermatology; 2012; 225(2):135-40. PubMed ID: 23006507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors.
    Agero AL; Dusza SW; Benvenuto-Andrade C; Busam KJ; Myskowski P; Halpern AC
    J Am Acad Dermatol; 2006 Oct; 55(4):657-70. PubMed ID: 17010747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toward evidence-based management of the dermatologic effects of EGFR inhibitors.
    LoRusso P
    Oncology (Williston Park); 2009 Feb; 23(2):186-94. PubMed ID: 19323301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors.
    Galimont-Collen AF; Vos LE; Lavrijsen AP; Ouwerkerk J; Gelderblom H
    Eur J Cancer; 2007 Mar; 43(5):845-51. PubMed ID: 17289377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous side-effects of EGFR inhibitors and their management.
    Ehmann LM; Ruzicka T; Wollenberg A
    Skin Therapy Lett; 2011 Jan; 16(1):1-3. PubMed ID: 21293833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trichomegaly of the eyelashes during therapy with epidermal growth factor receptor inhibitors: report of 3 cases.
    Fabbrocini G; Panariello L; Cacciapuoti S; Bianca D; Ayala F
    Dermatitis; 2012; 23(5):237-8. PubMed ID: 23010833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutaneous drug eruptions associated with the use of new oncological drugs.
    Belloni B; Schönewolf N; Rozati S; Goldinger SM; Dummer R
    Chem Immunol Allergy; 2012; 97():191-202. PubMed ID: 22613863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathology and management of dermatologic toxicities associated with anti-EGFR therapy.
    Fox LP
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):26-34. PubMed ID: 16736980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy.
    Tejwani A; Wu S; Jia Y; Agulnik M; Millender L; Lacouture ME
    Cancer; 2009 Mar; 115(6):1286-99. PubMed ID: 19170238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.